Skip to search formSkip to main contentSkip to account menu

eltrombopag

Known as: Eltrombopagum, eltrombopag [Chemical/Ingredient] 
An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet… 
National Institutes of Health

Related topics

Related topics

18 relations

Broader (3)

BenzoatesHydrazinesPyrazoles
Breast Cancer Resistance Protein Inhibitors [MoA]Eltrombopag olamineMPL protein, humanThrombopoietin Receptor Agonists [MoA]

Narrower (3)

PromactaRevoladeSB-497115-GR

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia.
Eltrombopag, a thrombopoietin (TPO) receptor agonist, is effective for treating refractory immune thrombocytopenia (ITP). However… 
2016
2016
Successful Treatment of a Diamond-Blackfan Anemia (DBA) Patient with Eltrombopag
DBA is a rare bone marrow failure syndrome clinically defined by onset of hypoproliferative anemia in early childhood… 
2015
2015
Age and Bone Marrow Cellularity are Associated with Response to Eltrombopag in Japanese Adult Immune Thrombocytopenia Patients: A Retrospective Single-Center Study.
In the present retrospective single-center study, we examined the efficacy and safety of eltrombopag, a thrombopoietin (TPO… 
2015
2015
The Thrombopoietin Receptor Agonist Eltrombopag Has DNA Repair Activity in Human Hematopoietic Stem and Progenitor Cells
Recent studies have uncovered a specific function of thrombopoietin (TPO) in the regulation of hematopoietic stem/progenitor cell… 
Review
2014
Review
2014
Use of eltrombopag in thrombocytopenia of liver disease
Second generation thrombopoietin agonists including eltrombopag and romiplostim act on the thrombopoietin receptor to increase… 
2014
2014
Eltrombopag for Refractory Severe Aplastic Anemia
Although the prognosis for patients with severe aplastic anemia (SAA) has improved in recent years, about 30% of patients remain… 
2010
2010
The Effect of Eltrombopag on Platelet Resistance to Apoptosis: The Role of the Bcl-Xl Pathway
Abstract 1158 INTRODUCTION: Immune thrombocytopenia (ITP) is typically characterized by increased platelet destruction and… 
2010
2010
Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia after MDS: A phase I/II study.
TPS184 Background: Patients with myelodysplastic syndromes (MDS) frequently develop thrombocytopenia for which the only effective… 
2010
2010
Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
The present invention was identified features to obtain a thromboplastin bopaek El and El thromboplastin bopaek ethanolamine salt… 
Review
2008
Review
2008
Eltrombopag: A TPO receptor agonist for the treatment of chronic idiopathic thrombocytopenic purpura
Eltrombopag is a TPO receptor agonist that is currently pending FDA approval for the treatment of ITP. This agent has been…